Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Social Networks
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. Hosting Providers
  14. CDN Services

We began analyzing https://www.dovepress.com/potential-role-of-immunotherapy-in-advanced-non-small-cell-lung-cancer-peer-reviewed-fulltext-article-OTT, but it redirected us to https://www.dovepress.com/potential-role-of-immunotherapy-in-advanced-non-small-cell-lung-cancer-peer-reviewed-fulltext-article-OTT. The analysis below is for the second page.

Title[redir]:
Potential role of immunotherapy in advanced non-small-cell lung cancer | OTT
Description:
Potential role of immunotherapy in advanced non-small-cell lung cancer Ramon Andrade de Mello,1–3 Ana Flávia Veloso,4 Paulo Esrom Catarina,4 Sara Nadine,5 Georgios Antoniou6 1Department of Biomedical Sciences and Medicine, University of Algarve, Faro, 2Faculty of Medicine, University of Porto, Porto, Portugal; 3Research Center, Cearense School of Oncology, Instituto do Câncer do Ceará, 4Oncology & Hematology League, School of Medicine, State University of Ceará (UECE), Fortaleza, Brazil; 5Instituto de Ciências Biomédicas Abel Salazar (ICBAS), University of Porto, Porto, Portugal; 6Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK Abstract: Immuno checkpoint inhibitors have ushered in a new era with respect to the treatment of advanced non-small-cell lung cancer. Many patients are not suitable for treatment with epidermal growth factor receptor tyrosine kinase inhibitors (eg, gefitinib, erlotinib, and afatinib) or with anaplastic lymphoma kinase inhibitors (eg, crizotinib and ceritinib). As a result, anti-PD-1/PD-L1 and CTLA-4 inhibitors may play a novel role in the improvement of outcomes in a metastatic setting. The regulation of immune surveillance, immunoediting, and immunoescape mechanisms may play an interesting role in this regard either alone or in combination with current drugs. Here, we discuss advances in immunotherapy for the treatment of metastatic non-small-cell lung cancer as well as future perspectives within this framework. Keywords: immunotherapy, non-small-cell lung cancer, nivolumab, pembrolizumab, ipilimumab, clinical trials, PD1, PDL1, CTLA4

Matching Content Categories {📚}

  • Health & Fitness
  • Science
  • Education

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🏙️ Massive Traffic: 50M - 100M visitors per month


Based on our best estimate, this website will receive around 75,579,999 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We don’t know how the website earns money.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Doi.org might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

cancer, patients, immune, lung, nsclc, tumor, immunotherapy, nivolumab, pdl, phase, treatment, advanced, tcells, response, inhibitors, cells, checkpoint, ipilimumab, clinical, trial, mgkg, trials, cell, pembrolizumab, ctla, results, therapy, nonsmallcell, aes, studies, showed, tremelimumab, versus, expression, oncol, tcs, tregs, atezolizumab, study, docetaxel, survival, chemotherapy, system, responses, safety, activity, group, squamous, nct, medical,

Topics {✒️}

pd-l1-selected stage iiib/iv chemo-refractory b-cell malignancies anti-pd-1/pd-l1 monotherapy tumor-specific t-cell response humanized anti-pd-1 mab anti-pd-l1-directed therapy t-cell receptor promotes including fast-track processing myeloid-derived suppressor cell antibody-producing plasma cells long-lived memory cells cd4+ car t-cells helper cd4+ t-cells dove medical press cd8+ t-cells function small-cell lung cancer small-cell lung cancer downregulates t-cell activation unrestrained t-cell activation anti-pd-1/pd-l1 high pd-l1 expression cytotoxic cd8+ t-cells effector t-cell activity lung cancer-specific measure including antigen-presenting cells low pd-l1 expression cd4+ t-cells differentiate initial apc-driven activation reprogram patient t-cells immune-related adverse events chimeric antigen receptors effective cell-mediated immunity cd8+ t-cells play highest pd-l1 expression 6-month progression-free survival specific author manuscript login pd-1/pd-l1 pathways favored authors 3research center inhibit tumor-induced immunosuppression drug-resistant tumor cells t-cell receptor host-protective antitumor responses phase ii trial tryptophan catabolism pathway line platinum-based therapy memory t-cells stage iii/iv cd4+ t-cells

Questions {❓}

  • Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer?
  • Immunotherapies for NSCLC: are we cutting the gordian helix?
  • Immunotherapy for lung cancer: for whom the bell tolls?
  • Nivolumab for advanced squamous cell lung cancer: what are the next steps?
  • Why has active immunotherapy not worked in lung cancer?
  • Why publish with us?

Social Networks {👍}(9)

External Links {🔗}(171)

Analytics and Tracking {📊}

  • Google Analytics
  • Google Tag Manager
  • Google Universal Analytics

Libraries {📚}

  • jQuery
  • Video.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Com/cm/ef49a3f1-d8c1-47d6-88fc-50e41130631f/airgap

4.66s.